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Abstract
Background: The development of a vaccine against hepatitis B virus (HBV) has been a major achievement in terms
of prevention of HBV infection. For the present study, we analysed the long-term immunogenicity and effectiveness
of HBV vaccination among healthcare students with different working seniorities.
Methods: A cross-sectional study of undergraduate and postgraduate students attending the Medical School of the
Second University of Naples was conducted between September 2012 and December 2014. HBV serum markers
were determined and multivariate logistic regression analysis was used to identify factors associated with the level
of long-term immunogenicity.
Results: Of the 2,932 subjects evaluated, only 33 (1.1 %) declared no history of vaccination. All vaccinated subjects
were HBsAg/anti-HBc negative, 459 of which had an anti-HBs titre <10 IU/L. The latter were younger, more likely to
be attending a healthcare profession school (i.e., dental hygienists, nursing, paediatric nursing, radiography and
midwifery) than a medical school (at either undergraduate or postgraduate level) and more likely to have been
vaccinated in infancy.
Conclusion: The results of this study suggest that assessment of HBV serum markers in workers potentially exposed
to hospital infections is useful to identify small numbers of unvaccinated subjects or vaccinated subjects with low
antibody titre, all of whom should be referred to a booster series of vaccinations.
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Background
Hepatitis B virus (HBV) can cause dreadful infectious
diseases and, as such, is a major global health problem
[1]. Infection can be asymptomatic or symptomatic, can
take the form of acute or chronic liver disease and is
potentially fatal. The World Health Organisation
(WHO) estimates that, globally, about 2 billion people
have been infected with HBV, more than 350 million are
chronically infected, and nearly one million per year die
from its acute or chronic sequelae [2]. The risk run by
healthcare personnel (HCP) of contracting HBV is four
times greater than that of the general adult population
[3]. The most common routes of transmission from
patients to HCP are needlestick and other sharps injuries,
followed by mucocutaneous exposure [4]. The risk of
transmission of the virus per needlestick injury from a
patient infected with HBV is 37–62 %, among the highest
risk rates for a virus [5].
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In addition to HCP, students and assistants in training
are also potentially exposed to hospital infections [6]. A
range of different measures and interventions, such as
the use of safety devices, has helped to reduce the risk of
HBV transmission to HCP, but the development of HBV
vaccines must be considered the major achievement in
terms of prevention of HBV infection [4].
Since 1991, there has been a compulsory vaccination
programme in Italy for infants: the procedure is reported
on a vaccination card, a document designed exclusively to
record basic identifying information and the immunization
services received. The vaccination coverage has been high
(94 %), and the programme has greatly reduced the inci-
dence of HBV infection [7]. All babies are vaccinated (at
month 3, 5 and 11) to prevent the risk of acquiring HBV
infection by perinatal and familial transmission; moreover,
during the first 12 years of application of the programme,
all children aged 12 were also vaccinated to prevent HBV
transmission by unsafe sexual activity or intravenous drug
use. This strategy permitted the programme to cover the
Italian population aged 0–24 years by 2003 [8].
It is generally observed that antibody titres decline over
time following immunization, resulting in an increased
rate of infection, especially when the titre of the antibody
to hepatitis B surface antigen (HBsAg) falls below the
protective cut-off level of ≥10 mIU/mL [9]. The present
study was therefore carried out to evaluate the long-term
immunogenicity and effectiveness of the Italian HBV
vaccination programme in students attending the medical
and healthcare schools of the Second University of Naples,
Italy, and to identify independent predictive factors of
long-term immunogenicity.
Methods
This study was conducted at the Second University of
Naples, Naples, Italy, from September 2012 to December
2014. Based on the risk assessment document, during this
period we carried out a health surveillance programme of
third and sixth year medical school students, first and
third year health profession school students (three-year
nursing, dental hygienists, paediatric nursing, radiography
and midwifery courses), and first and third year students
of the university’s specialisation schools (all of whom were
post-medical school students). All were actively recruited
before any possible exposure to risky procedures or patients
connected with the educational path, as established by our
health protocol [10, 11]. HBV serum markers (HBsAg, anti-
HBs and total anti-HBc) were determined at year 3 for the
medical school students, and year 1 for students of the
health profession schools and of the specialisation schools.
HBsAg titre was re-evaluated again at a later time only in
subjects with a low (<10 IU/L) anti-HBs titre.
After obtaining informed written consent, all students
visited for the first time were asked to complete a pre-
coded questionnaire stating their age, gender, hepatitis
B vaccination status, previous exposure to HBV and
educational level. The information on HBV vaccination
given by the students was always checked against their
vaccination cards. A blood sample was taken from each
participant under strict aseptic conditions in a plain
vaccutainer. Blood was allowed to clot and serum was
separated and stored at −20 °C until testing. HBV
serum markers (HBsAg, anti-HBs and total anti-HBc)
were determined using commercial immunoenzymatic
assays (Abbott Laboratories, North Chicago, IL, USA).
Anti-HBs titres were extrapolated from a calibration
curve generated using the WHO reference standard
and are expressed in IU/L. In particular, actual values
were obtained for anti-HBs titres between 10 and 400 IU/
mL, and for this interval the geometric mean was calculated
using standard procedures; for values <10 IU/mL or >400
IU/mL, the laboratory readout indicated only either “under
10 IU/mL” or “over 400 IU/mL”, respectively.
According to Italian legal guidelines for observational
studies, ethical approval for conducting this survey was
unnecessary and, accordingly, cross-sectional studies did
not require formal approval by local institutional review
boards [12]. Personal information on the subjects included
in the study was protected according to Italian law [13].
Statistical analysis was performed with StatGraph v3.0.
Continuous variables are given as mean±standard
deviation, and categorical variables as the absolute
value and relative frequency. Differences in mean were
evaluated using an unpaired Student t-test, and the
chi-squared test was applied to categorical variables. A
p-value of <0.05 was considered to be statistically
significant.
Results
In total, 2,932 students attending the medical school, the
healthcare profession schools and the specialisation
schools of the Second University of Naples were
screened from September 1, 2012, to December 31,
2014. On the questionnaire, 2,899 (98.9 %) students
declared a history of HBV vaccination. The remaining 33
(1.1 %) were not born in Italy: 32 were HBsAg/anti-HBs/
anti-HBc negative, and one was HBsAg positive; 23 were
attending a healthcare profession school, seven the
medical school and three were specialising doctors. All
were being evaluated for HBV for the first time.
The HBsAg positive subject was attending the first year
of the thoracic surgery specialisation school, and on the
advice of the infectious disease specialist, was started on a
course of antiviral therapy and included in a follow-up
programme for the monitoring of viral load. The student
returned to work under the obligation of using personal
protective equipment (Kevlar cut-resistant gloves), had to
present at the customary medical check-ups with a
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reduced periodicity of six months, and was temporarily
prohibited from carrying out any highly invasive surgery.
The 2,899 vaccinated subjects were all HBsAg/anti-HBc
negative. One thousand seven hundred and forty one
students (60.1 %) were female and 2,868 (98.9 %) were of a
Caucasian Italian ethnic background; 994 had received a
course of 3 paediatric doses (10 μg) of recombinant
hepatitis B vaccine at their 3rd, 5th and 11th month of
postnatal life, and 1,905 had received a course of 3 adult
doses (20 μg) of the same vaccine when 12 years old. The
majority (84.2 %) of the students had an anti-HBs titre >10
IU/L. Only 362 students were sure that their mothers were
HBV negative at the time of giving birth to them (Table 1).
Compared with students vaccinated at age 12 years,
those vaccinated in infancy were younger (21.5 ± 1.0 vs.
28.0 ± 4.5, p <0.000), more frequently female (72 % vs.
54 %, p <0.000) (Table 2) and had a significantly lower
prevalence of individuals with a low (<10 IU/L) anti-
HBs titre (12.3 vs. 22.6 %) (Table 2).
The subjects with an anti-HBs titre <10 IU/L were
younger, more frequently attending a healthcare profession
school, and had more frequently been vaccinated in infancy
(Table 3 and Fig. 1). The 32 unvaccinated HBsAg/anti-
HBs/anti-HBc negative subjects were required to undergo
the complete HBV prophylaxis programme.
Discussion
In 2013, the Integrated Epidemiological System for Acute
Viral Hepatitis (SEIEVA) reported an incidence of HBV
infections in Italy of only 1 per 100,000 individuals; about
20 % of acute HBV infections concerned immigrants,
especially from Eastern Europe and Africa, areas highly
endemic for HBV [14]. This large reduction in the
incidence of HBV infection is certainly also linked to
the vaccination programme for infants and 12-year-old
adolescents in Italy since 1991.
No student that had been vaccinated was found to
have been infected with HBV, as reflected by the absence
of positivity to serum HBsAg or anti-HBc after a mean
period of nearly 18 years. Thus, the efficacy of the
programme is excellent (i.e., 100 %). However, we found
that factors such as older age decreased immunogenicity,
and that low levels of anti-HBs could be predictive of
non-protection. Other factors, such as smoking and
obesity, not assessed in our study, may also be involved
in decreased immunogenicity [15–17].
Several studies have reported that 85–90 % of those vac-
cinated as adolescents have anti-HBs levels >10 mIU/mL
when measured 10 years after vaccination. This percent-
age was 40–60 % for those vaccinated as infants, as
measured 15–20 years after vaccination [18, 19]. The
possible causes of the low anti-HBs titres in adult
subjects vaccinated in infancy could be a lower inter-
action between B and T cells in babies, and in some
cases, the presence of serum anti-HBs in mothers
might affect the response to the HBV vaccine in babies
[20, 21]. This is coherent with our finding that 87.7 % of
students vaccinated during adolescence had an anti-HBs
titre >10 IU/L, while only 77.4 % of those vaccinated in
infancy had a titre >10 IU/L. Closer analysis of our results
revealed that healthcare profession students, who were
mainly female, had a higher percentage of individuals with
Table 1 Demographics of vaccinated, HBsAg-negative students
Characteristic Value
No. of subjects 2,899
Age in years 26 ± 4.8
Female Reported HBV status of mothers 1,741 (60.1) 362
Place of birth: Italy 2,868 (98.9)
Elsewhere 31 (1.1)
Continuous variables are given as mean±SD; categorical variables are given as
n° (%)
Table 2 Characteristics of the 2,899 vaccinated students stratified by age at vaccination
Vaccinated in infancy Vaccinated at age 12 years p
No. of students 994 1,905
Age in years 21.8 ± 1.0 28.0 ± 4.5 0.000
Females 715 (72) 1,026 (54) 0.000
Place of birth: Italy 987 (99.3) 1,881 (98.7) n.s.
Elsewhere 7 (0.7) 24 (1.3)
Attending: School of medicine 56 (5.6) 839 (44) 0.000*
Healthcare profession school 938 (94.4) 468 (24.6)
Postgraduate medical school 0 598 (31.4)
Years since vaccination 22.1 ± 1.1 16.1 ± 3.1 0.000
Students with HBsAb <10IU/L 224 (22.6) 235 (12.3) 0.000
Students with HBsAb >10 IU/L 770 (77.4) 1670 (87.7) 0.000
*Healthcare professions school students vs. all medical school students (graduate + postgraduate)
Continuous variables are given as mean±SD; categorical variables are given as n° (%)
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an anti-HBs titre <10 IU/L. Indeed, this group was the
youngest (they were assessed during their first year of
studies, rather than during the third year, as done for the
medical students, as required by the risk assessment docu-
ment) and therefore had the highest number of subjects
who had received compulsory vaccination in infancy.
HCP and healthcare students are reported to have
the highest occupational risk for HBV infection, with
approximately 66,000 HBV infections per year worldwide.
Therefore, testing medical students for anti-HBs levels
may be warranted as they represent a high-risk
population [22–24]. This is particularly relevant in
countries where HBV vaccination programmes for
infants and adolescents has been introduced but no
post-vaccination serological testing is done, making it
impossible to identify unvaccinated subjects [25, 26].
In our group, 33 students had not been vaccinated,
one of whom had acquired an HBV infection. Italian
law (Article 279 of Legislative Decree n. 8, 19 April
2008) requires only to review the vaccination status of
HCP and healthcare students prior to employment or
to enrolment in a course with a documented possible
risk of HBV contagion. However, the decree currently
only recommends that unvaccinated individuals be
vaccinated; in other words, there is no clear legal obli-
gation to do so. The vaccination procedure is charged
to the employer, and the occupational physician must
perform the vaccination procedure [27], but even if
the non-vaccination of an unvaccinated worker does
not lead to automatic discharge, it may lead the occu-
pational physician to limit activities deemed risky.
In our case, all 33 unvaccinated subjects were sent
for vaccination and re-evaluation of anti-HBs titre.
The HBsAg positive subject was put on antiviral
therapy and was included in a follow-up programme
monitoring viral load.
In HCP and healthcare students, it is necessary to
assess anti-HBs titre either at matriculation or at the
start of employment in order to identify subjects with
levels <10 IU/L. In fact, although the current WHO
view is that subjects with an anti-HBs titre <10 IU/L
still retain memory immunity, and no booster dose is
Table 3 Characteristics of students stratified by anti-HBs titre
<10 IU/L >10 IU/L P
No. of students 459(15.8) 2,440 (84.2)
Age in years 24 ± 5.3 26 ± 5.1 0.000
Females 269 (58.6) 1,472 (60.3) n.s
Attending: School of medicine 112 (24.4) 792 (32,5) 0.0001*
Healthcare professions school 254 (55.3) 1,175 (48.1)
Postgraduate medical school 93 (20.3) 473 (19.4)
Vaccinated in infancy 235 (51.2) 759 (31.1) 0.000
at age 12 years 224 (48.8) 1,681 (68.9)
*Healthcare profession school students vs. all medical school students (graduate + postgraduate). Continuous variables are given as mean±SD; categorical
variables are given as n° (%)
Fig. 1 Number of vaccinated students with an anti-HBs titre <10 IU/L or >10 IU/L, stratified by year of vaccination
Lamberti et al. Journal of Occupational Medicine and Toxicology  (2015) 10:41 Page 4 of 6
necessary as part of a routine immunization programme
[27], a more protective approach should be adopted for
healthcare workers under continuous risk of exposure to
HBV [28, 29]. To distinguish between non-responsive
subjects and those whose titres have waned over time but
who are still protected, a ‘challenge’ or ‘booster’ dose should
be administered and titres rechecked 1–2 months later.
Those presenting with titres ≥10 IU/L can be considered
protected and not needing additional testing or vaccination,
whereas those presenting with titres that are still <10 IU/L
after the challenge dose should be referred to a vaccination
programme. Indeed, previous studies of young subjects
who had been vaccinated in infancy have indicated
that a single-dose booster may not reliably induce an
anti-HBs response, suggesting that humoral memory
immunity reduces with time. Lu CY et al. showed that
the HBsAg-specific T cell immune response was negative in
27.2 % of subjects who had received a booster 15 to 18
years after HBV vaccination in infancy [30]; a more recent
study of young adults (ages ranging from 18.6 to 20.5 years)
who had been immunized against HBV as infants reported
that nearly 20 % of subjects with HBsAb <10 IU/L failed to
respond to a booster injection [31].
Conclusion
The present study evaluates the efficacy and immunogen-
icity of HBV vaccination in a large series of subjects with a
high risk of being exposed to HBV. The results of this study
suggest that assessment of HBV markers is worthwhile to
identify the small number of medical students and HCP
that may not have been vaccinated, such as immigrants
from countries without universal immunisation, and HBV
carriers that exist for various reasons, including rare failure
in protection or uptake after immunisation.
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